Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial (Q36249636)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial |
scientific article |
Statements
1 reference
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial (English)
1 reference
Richard E Pratley
1 reference
Michael A Nauck
1 reference
Timothy Bailey
1 reference
Sebastiano Filetti
1 reference
Alan J Garber
1 reference
Anne B Thomsen
1 reference
Sabina Furber
1 reference
1860-LIRA-DPP-4 Study Group
1 reference
1 reference
Identifiers
1 reference